eligibility_summary
Include: age ≤65, stable vitals, no severe infection, no grade II–IV GVHD, no organ failure. Exclude: age >65, unstable vitals, severe infection, grade II–IV GVHD, organ failure (heart/liver/kidney), CNS leukemia, or allergy to regimen drugs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06339775 is a Phase 4, single-arm study in relapsed B‑ALL post–allo-HSCT testing blinatumomab followed by donor lymphocyte infusion (DLI). Blinatumomab is a bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B‑lymphoblasts and CD3 on T cells, redirecting and activating cytotoxic T cells to lyse CD19+ leukemia via immune synapse formation and perforin/granzyme–cytokine pathways. DLI is an adoptive cellular therapy (donor mononuclear/T‑cell infusion) to boost graft‑versus‑leukemia (GVL) immunity. Targets/pathways: CD19+ B cells, CD3/TCR signaling, T‑cell cytotoxic effector pathways, and augmentation of alloreactive donor T‑cell responses.